[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

APAC to Dominate Global Hepatocellular Carcinoma Market to 2022, Expects RNCOS in Its New Study Available at MarketPublishers.com

27 Apr 2017 • by Natalie Aster

LONDON – Nowadays, hepatocellular carcinoma (HCC), a.k.a. malignant hepatoma, is amid the most common types of liver cancer globally. The marketplace is expected to keep on gaining traction owing to manifold drivers, such as escalating number of diseases associated with hepatitis B or C virus; the rising incidence of obesity, diabetes and non-alcoholic fatty liver diseases.

Additionally, population aging, sedentary lifestyle that many people have, rising investments in R&D activities ignite the market growth. Yet, such factors as regulatory issues and drug failures in pipeline restrain this growth.

The global market for HCC drugs is set to observe a considerable growth in the years ahead. As of now, Nexavar represents the only approved target drug for the advanced condition of HCC. Miripla is an exception: this drug is approved only in Japan. Meanwhile, the competitive scenario of the market is projected to be tense over the next 2-3 years.

As of 2016, North America grabbed the lion’s share of the total marketplace. Geography-wise, the APAC market will be growing at the fastest rate in the offing owing to such factors as the escalating incidence of diabetes, cancer, hepatitis infections, and other chronic disorders.

New research study “Global Hepatocellular Carcinoma Drug Sales (Nexavar&Miripla), Pipeline Analysis and Global Market Forecast 2022” drawn by RNCOS E-Services offers an insightful analysis of the historical, current and projected state of the global HCC market. The report examines the market dynamics, highlighting the key driving and restraining factors. The latest innovations and market growth opportunities are thoroughly investigated in the publication.

Additionally, the report provides detailed information on HCC drugs at various stages of clinical development. It comprises a detailed segmentation of HCC drugs under clinical development on the basis of clinical phase.

Also, this comprehensive study touches upon various mergers and acquisitions in the global space, delves deep into the competitive landscape, besides focusing on the prominent participants active in the global HCC drug market and providing data on their financial performance and product portfolios.

New research publications by our partner are available at RNCOS E-Services page at MarketPublishers.com.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest